Glaxosmithkline | GSK - Selling And Administration Expenses

Stock Price
53.12
Daily Change
4.83 10.00%
Monthly
9.05%
Yearly
52.47%
Q1 Forecast
50.58

Glaxosmithkline reported GBP2.91B in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.25B 40M Jun/2025
Amgen USD 1.7B 9M Sep/2025
AstraZeneca USD 148M 4.86B Sep/2025
Aurora Cannabis CAD 41.79M 3.84M Sep/2025
Bausch Health Companies USD 795M 99M Sep/2025
Bristol-Myers Squibb USD 1.79B 76M Sep/2025
Canopy Growth CAD 29.53M 999K Sep/2025
Corcept Therapeutics USD 106.97M 3.12M Sep/2025
Drreddys Laboratories INR 26.92B 3.74B Dec/2025
Eli Lilly USD 2.74B 12.3M Sep/2025
GlaxoSmithKline GBP 2.16B 19M Sep/2025
Glaxosmithkline GBP 2.91B 817.89M Sep/2025
J&J USD 6.75B 831M Dec/2025
Merck USD 2.63B 0 Sep/2025
Novartis USD 3.31B 134M Sep/2025
Pacira USD 91.8M 14.6M Sep/2025
Perrigo USD 245.7M 27.4M Sep/2025
Pfizer USD 3.19B 209M Sep/2025
Prestige Brands USD 28.04M 419K Sep/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
Supernus Pharmaceuticals USD 179.68M 117.46M Sep/2025
Takeda JPY 282.78B 29.23B Dec/2025
Teva Pharmaceutical Industries USD 1.12B 147M Dec/2025
Zoetis USD 579M 29M Sep/2025